Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program

NEXT STORY
Olema Oncology to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference
PREV STORY
Glycotope announces licensing agreement with ONK Therapeutics for humanized GlycoBody targeting TA-MUC1
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Ascendis Pharma Announces Completion of Target Enrollment in Phase 3 Trial of TransCon Growth Hormone for Pediatric Growth Hormone Deficiency

COPENHAGEN, Denmark, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical ...

author_avatar
NASDAQ Market News

Inflammatory Brain Disorders Conference to be held online May 13-14, 2021

author_avatar
NASDAQ Market News

Arecor Announces Positive Headline Results for the First Phase I Clinical Trial of AT247, a Novel Ultra Rapid Acting Formulation of Insulin

author_avatar
NASDAQ Market News